ANKS6 Antibody

Code CSB-PA718074LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human endometrial cancer using CSB-PA718074LA01HU at dilution of 1:100

  • Immunofluorescent analysis of HepG2 cells using CSB-PA718074LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)

Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) ANKS6 Polyclonal antibody
Uniprot No.
Target Names
ANKS6
Alternative Names
ANKRD14 antibody; Anks6 antibody; ANKS6_HUMAN antibody; ankyrin repeat and SAM domain containing protein 6 antibody; Ankyrin repeat and SAM domain-containing protein 6 antibody; Ankyrin repeat and sterile alpha motif domain containing 6 antibody; ankyrin repeat domain 14 antibody; ankyrin repeat domain containing protein 14 antibody; Ankyrin repeat domain-containing protein 14 antibody; SAM domain containing protein 6 antibody; SAM domain-containing protein 6 antibody; SamCystin antibody; SAMD6 antibody; sterile alpha motif domain containing 6 antibody; sterile alpha motif domain containing protein 6 antibody; Sterile alpha motif domain-containing protein 6 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Ankyrin repeat and SAM domain-containing protein 6 protein (1-132AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The ANKS6 Antibody (Product code: CSB-PA718074LA01HU) is Non-conjugated. For ANKS6 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA718074LB01HU ANKS6 Antibody, HRP conjugated ELISA
FITC CSB-PA718074LC01HU ANKS6 Antibody, FITC conjugated
Biotin CSB-PA718074LD01HU ANKS6 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, IHC, IF
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Required for renal function.
Gene References into Functions
  1. Data indicate the importance of ANKS6 in human kidney development and suggest a mechanism by which mutations in ANKS6 may contribute to an nephronophthisis-like phenotype in chronic kidney disease. PMID: 24610927
  2. ANKS6 as a new NPHP family member that assembles a distinct module of nephronophthisis-associated proteins, encompassing NEK8, INVS and NPHP3. PMID: 23793029
  3. Location, sequence and structure of the gene encoding human SamCystin have been determined. PMID: 18434273
Involvement in disease
Nephronophthisis 16 (NPHP16)
Subcellular Location
Cell projection, cilium. Cytoplasm.
Database Links

HGNC: 26724

OMIM: 615370

KEGG: hsa:203286

STRING: 9606.ENSP00000297837

UniGene: Hs.406890

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
×
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*